CINCINNATI--(BUSINESS WIRE)-- Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from ...
NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in ...
Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), ...
Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that ...
Pennington Biomedical’s Dr. Jeff Keller and Dr. Aron Culotta of Tulane to lead collaboration of AI researchers, neuroscientist and drug developers Answer ALS is proud to announce the launch of a ...
PrimeC, a new drug used to treat Amyotrophic lateral sclerosis (ALS) disease by NeuroSense Therapeutics Ltd. has been successful in proving its efficacy in its clinical study Phase 2b and it’s ...
AB Science SA (Euronext – FR0010557264 – AB) today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, ...
ALS, which is also known as Lou Gehrig’s Disease, is a rare neurological disease that affects motor neurons — the nerve cells. Why are so many amyotrophic lateral sclerosis (ALS) drug trials are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback